KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) EBT Margin (2016 - 2025)

Ionis Pharmaceuticals has reported EBT Margin over the past 17 years, most recently at 75.38% for Q4 2025.

  • Quarterly results put EBT Margin at 75.38% for Q4 2025, up 12290.0% from a year ago — trailing twelve months through Dec 2025 was 0.32% (up 6566.0% YoY), and the annual figure for FY2025 was 0.17%, up 6550.0%.
  • EBT Margin for Q4 2025 was 75.38% at Ionis Pharmaceuticals, up from 81.93% in the prior quarter.
  • Over the last five years, EBT Margin for IONS hit a ceiling of 6176.55% in Q2 2025 and a floor of 119.44% in Q1 2024.
  • Median EBT Margin over the past 5 years was 55.23% (2021), compared with a mean of 275.76%.
  • Biggest five-year swings in EBT Margin: tumbled -40405bps in 2022 and later surged 620594bps in 2025.
  • Ionis Pharmaceuticals' EBT Margin stood at 374.86% in 2021, then plummeted by -108bps to 29.19% in 2022, then skyrocketed by 97bps to 0.85% in 2023, then plummeted by -5474bps to 47.53% in 2024, then soared by 259bps to 75.38% in 2025.
  • The last three reported values for EBT Margin were 75.38% (Q4 2025), 81.93% (Q3 2025), and 6176.55% (Q2 2025) per Business Quant data.